Free tools, free alerts. Create a free account to get sector-matched alerts and save your searches.
Create free account →
NAFDAC has issued multiple alerts and public notices in August 2026, including blacklisting a UK supplier, placing a local company's products on watchlist, seizing substandard antimalarials, warning about counterfeit toothpaste, and highlighting drug safety risks. These actions signal heightened regulatory scrutiny on product quality and safety, requiring Nigerian SMBs in the pharmaceutical, healthcare, and consumer goods sectors to strengthen their supply chain and compliance measures.
Pharmaceuticals
Healthcare
Consumer Goods
Importers and Distributors
Retailers and Vendors
Public Notice on Blacklisting Ayrtons Saunders Ltd, Uk
NAFDAC
NAFDAC blacklists Ayrtons Saunders Ltd, UK, and informs the public and stakeholders of this action.
Businesses dealing with this supplier must cease transactions and find alternative sources; potential supply chain disruptions.
Public Alert No. 043/2026-NAFDAC Places Products Marketed by Mofus Nigeria Ltd on Watchlist Pending Regulatory Investigation
NAFDAC
NAFDAC places products marketed by Mofus Nigeria Ltd on a watchlist pending investigation.
SMBs distributing or selling Mofus products should verify compliance and prepare for possible recalls or restrictions.
Public Alert No. 042/2026-Alert on the Seizure of Suspected Substandard and Falsified BPPL Artemether/Lumefantrine 80mg/480mg
NAFDAC
NAFDAC alerts on the seizure of suspected substandard and falsified antimalarial medicine BPPL Artemether/Lumefantrine.
Pharmacies and distributors must check stock for this product and ensure they source from authorized suppliers.
Public Alert No. 041/2026 – Alert on Suspected Counterfeit ORACIRE+ Toothpaste
NAFDAC
NAFDAC warns of counterfeit ORACIRE+ toothpaste circulating as ORACARE+.
Retailers and consumers should verify product authenticity; businesses must ensure their inventory is genuine to avoid legal issues.
Public Alert No: 039/2026 – Alert on the Risk of Drug Poisoning Associated with Concurrent Use of Gabapentinoids and Other Medicines
NAFDAC
NAFDAC warns about increased risk of drug poisoning when gabapentinoids are used with certain other medicines.
Pharmacists and healthcare providers must counsel patients on drug interactions; SMBs in healthcare should update dispensing practices.
Heightened enforcement against substandard and counterfeit products.
Need for robust supplier due diligence and verification of product authenticity.
Potential for product recalls or market withdrawals affecting inventory.
Increased scrutiny on pharmaceutical and consumer goods supply chains.
Opportunity for compliant businesses to gain consumer trust.
1
Review and update supplier lists to exclude blacklisted entities.
2
Verify product authenticity with NAFDAC registration numbers before purchase.
3
Conduct internal audits of inventory for affected products.
4
Train staff on identifying counterfeit products and reporting suspicious items.
5
Stay informed on NAFDAC alerts and adjust business practices accordingly.